To begin with, Zhang et al. presented evidence in this direction in a study primarily exploring the role of CD4+CD25+ Tregs in modulating the immune response against HCC and investigating the potential therapeutic benefits of depleting these cells. This evidence concerns the gene CD4 and hepatocellular carcinoma.